Therma Bright Inc V.THRM

Alternate Symbol(s): TBRIF

Healthcare Medical Devices

Therma Bright Inc. is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. The Venowave is a medical compression pump that is lightweight, compact, battery operated, designed to treat and alleviate the symptoms associated with poor circulation.

TSXV:THRM - Post by User

Therma Bright Inc

<< Previous

Bullboard Posts

Next >>

Post by TuTomekon Oct 28, 2021 2:26pm

296 Views

Post# 34060050

from Proactive website

Therma Bright says 'on track' for FDA approval of its COVID-19 rapid antigen saliva test, AcuVid

"Our robust bench tests and clinical performance results, provide us with confidence that we will be able to bring a viable solution to limit the spread of this virus in our communities," said Rob Fia, CEO of Therma Bright.

Therma Bright added it has identified three clinical study sites to conduct a point-of-care clinical performance study

Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) said it is on track to receive the US Food and Drug Administration's (FDA) approval for its AcuVid coronavirus (COVID-19) Rapid Antigen Saliva test.

The Toronto-based company said it had responded to FDA’s questions and suggestions, while also completing additional documentation and lab tests required by the federal agency.

"We are on track to make AcuVid™ the first COVID-19 Rapid Antigen Saliva Test to receive FDA approval. Our robust bench tests and clinical performance results, provide us with confidence that we will be able to bring a viable solution to limit the spread of this virus in our communities," said Rob Fia, CEO of Therma Bright.

<< Previous

Bullboard Posts

Next >>

Odd Burger to add 40 locations in Florida